Elevance Health Reports Q4 & FY25 Results; Issues Significantly Lower FY26 EPS & Revenue Guidance

summarizeSummary

Elevance Health reported fourth quarter 2025 results that were in line with expectations, showing increased operating revenue and diluted EPS. However, full year 2025 adjusted diluted EPS declined compared to the prior year, and operating cash flow also decreased. The most significant market-moving information is the company's full year 2026 outlook, which projects a substantial decline in both GAAP and adjusted diluted EPS, as well as a low single-digit decline in total operating revenue. Furthermore, the company anticipates significant medical membership attrition, particularly in its Commercial Risk-Based, Medicaid, and Medicare Advantage segments, projecting a loss of over 1.3 million members. This negative guidance, coupled with an increase in the benefit expense ratio reflecting higher medical cost trends, indicates a challenging year ahead for the company.

check_boxKey Events

• Full Year 2025 Performance

  Reported full year 2025 operating revenue of $197.6 billion, an increase of 13%, but adjusted diluted EPS declined by 8.3% to $30.29 compared to the prior year.

• Significantly Lower FY2026 EPS Guidance

  Projected full year 2026 adjusted diluted EPS to be at least $25.50, a substantial decrease from the $30.29 reported for full year 2025.

• Negative Revenue Outlook

  Forecasted a low single-digit decline in total operating revenue for full year 2026, following a 12.8% increase in 2025.

• Projected Membership Attrition

  Anticipates a decrease in total medical membership to 43.175-43.875 million by year-end 2026, down from 45.232 million in 2025, with notable declines in Commercial Risk-Based, Medicaid, and Medicare Advantage.

auto_awesomeAnalysis

Elevance Health reported fourth quarter 2025 results that were in line with expectations, showing increased operating revenue and diluted EPS. However, full year 2025 adjusted diluted EPS declined compared to the prior year, and operating cash flow also decreased. The most significant market-moving information is the company's full year 2026 outlook, which projects a substantial decline in both GAAP and adjusted diluted EPS, as well as a low single-digit decline in total operating revenue. Furthermore, the company anticipates significant medical membership attrition, particularly in its Commercial Risk-Based, Medicaid, and Medicare Advantage segments, projecting a loss of over 1.3 million members. This negative guidance, coupled with an increase in the benefit expense ratio reflecting higher medical cost trends, indicates a challenging year ahead for the company.